XIO Group

Investment decisions sit with Chief Executive Officer Joseph Pacini and the partnership group, which includes Managing Partner Athene Li and Partner Carsten Geyer. Pacini's background running Blackstone's Asia-Pacific private equity operations makes him the central figure in both origination and committee-level calls. The firm has not publicly detailed a formal investment-committee structure beyond the core partnership.

Beginning in 2017, China imposed strict curbs on outbound acquisitions, directly targeting the kind of deals XIO was built to execute — takeovers of Western companies with the aim of relocating capabilities or capturing the China market. The firm's deal flow slowed significantly, and by 2019 it was widely reported to be reassessing its model (public record). XIO has not publicly announced a revised strategy or new fund close since that regulatory shift.

XIO's flagship and only publicly known fund closed at approximately $1.8 billion in 2016 (per Reuters, 2016). It targeted control buyouts in industrials and healthcare, primarily in Europe and North America, with an explicit thesis of China-driven value creation. No subsequent fund has been publicly announced.

Two high-profile acquisitions defined the portfolio: Lumenis, an Israeli maker of medical lasers, acquired in 2015, and a subsidiary of Switzerland's Straumann Group focused on dental implants. Both fit the firm's pattern of acquiring regulated, technology-heavy healthcare assets with clear China-market applications.

The firm has not publicly disclosed its limited partners. Given Pacini's background and the fund's cross-border thesis, institutional investors in Asia and the Middle East are widely assumed to be significant backers, but no sovereign wealth fund or pension fund has confirmed participation in the public record.